アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - imatinib mesylate (unii: 8a1o1m485b) (imatinib - unii:bkj8m8g5hi) - imatinib 100 mg - newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. patients with philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all). pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) in combination with chemotherapy. adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with aggressive systemic mastocytosis without the d816v c-kit mutation or with c-kit mutational status unknown. adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the fip1l1-pdgfrα fusion kinase (mutational analysis or fluorescence in situ hybridiz

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

a-s medication solutions - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 8 mg - doxazosin mesylate tablets are indicated for the treatment of the signs and symptoms of bph. doxazosin mesylate tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood press

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

carilion materials management - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see precautions) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate tablets or to any component of the tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

cardinal health - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see precautions) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

remedyrepack inc. - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see precautions ) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

apopharma usa, inc. - deferoxamine mesylate (unii: v9tko7eo6k) (deferoxamine - unii:j06y7mxw4d) - deferoxamine mesylate for injection, usp, is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. acute iron intoxication deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. chronic iron overload deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relati

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

remedyrepack inc. - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see precautions ) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

remedyrepack inc. - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see precautions ) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

remedyrepack inc. - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see precautions ) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.